KYTX Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. (KYTX) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.74 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.2% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Kyverna Therapeutics, Inc.
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.